Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a $137.00 price target by investment analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Oppenheimer Holdings, Inc.’s price target points to a potential upside of 10.68% from the company’s current price. Oppenheimer Holdings also issued estimates for Zimmer Biomet Holdings’ Q3 2017 earnings at $1.73 EPS, Q4 2017 earnings at $2.30 EPS, FY2017 earnings at $8.24 EPS and FY2018 earnings at $8.82 EPS.
ZBH has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Thursday, April 13th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Zimmer Biomet Holdings in a report on Tuesday, May 16th. They issued a “sell” rating and a $92.00 target price on the stock. Canaccord Genuity restated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Wells Fargo & Company downgraded shares of Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Finally, Morgan Stanley boosted their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, July 17th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet Holdings currently has an average rating of “Buy” and an average target price of $138.05.
Shares of Zimmer Biomet Holdings (NYSE ZBH) opened at 123.78 on Friday. The firm’s 50-day moving average is $127.89 and its 200 day moving average is $121.20. Zimmer Biomet Holdings has a 52-week low of $95.63 and a 52-week high of $133.49. The stock has a market capitalization of $24.98 billion, a price-to-earnings ratio of 35.25 and a beta of 1.21.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The business’s quarterly revenue was up 1.1% on a year-over-year basis. Equities analysts expect that Zimmer Biomet Holdings will post $8.36 EPS for the current year.
In other news, VP Chad F. Phipps sold 6,200 shares of the company’s stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $116.76, for a total value of $723,912.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the company. Enterprise Financial Services Corp boosted its stake in shares of Zimmer Biomet Holdings by 0.3% in the second quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock valued at $340,000 after buying an additional 9 shares during the last quarter. Alpha Windward LLC boosted its stake in shares of Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock valued at $202,000 after buying an additional 18 shares during the last quarter. Sandy Spring Bank boosted its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares during the last quarter. Finally, Cleararc Capital Inc. boosted its stake in shares of Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock valued at $598,000 after buying an additional 25 shares during the last quarter. 84.37% of the stock is owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
